OmniAb, Inc.
OABI
Positions held
Your positionsOABI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $677.52M | Enterprise value | $644.44M | Trailing P/E | — | Forward P/E | -15.93 |
| PEG | — | Price / book | 2.60 | Beta | 1.37 | Dividend yield | 0.00% |
| Revenue growth | 2.4% | Earnings growth | — | Gross margin | 98.3% | Operating margin | -49.5% |
| Profit margin | -115.1% | ROE | -17.0% | ROA | -8.3% | Debt / equity | 0.07 |
| Current ratio | 4.80 | Free cash flow | -$285,000 | Analyst recommendation | strong_buy | Mean target | $8.33 |
| 52w high | $5.43 | 52w low | $1.30 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $13.4M | $14.4M | $8.4M | $2.2M | $3.9M |
| Op margin | -49.5% | -54.3% | -188.2% | -810.2% | -493.2% |
| Net income | -$5.9M | -$7.7M | -$14.2M | -$16.5M | -$15.9M |
| Gross margin | 95.5% | 99.9% | 99.9% | 98.7% | 93.3% |
| Gross profit | $12.8M | $14.4M | $8.4M | $2.2M | $3.6M |
| Operating income | -$6.6M | -$7.8M | -$15.8M | -$18.1M | -$19.2M |
- Revenue -7% vs prior quarter ($13M vs $14M).
- Gross margin 95.5% (was 99.9% prior quarter).
- Operating margin expanded to -49.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $18.7M | $26.4M | $34.2M | $59.1M | — |
| Op margin | -369.5% | -282.3% | -203.2% | -45.1% | — |
| Net income | -$64.8M | -$62.0M | -$50.6M | -$22.3M | — |
| Gross margin | 98.4% | 100.0% | — | — | — |
| Gross profit | $18.4M | $26.4M | — | — | — |
| Operating income | -$69.0M | -$74.5M | -$69.4M | -$26.6M | — |
Headlines — positive tone
• [OK · fundamentals] All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
News
2026-10-07 · OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth
2026-10-06 · All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
2026-09-14 · OmniAb to Host Investor & Analyst Day on October 6, 2026
2026-08-28 · Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?
2026-08-28 · VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
2026-08-26 · OmniAb to Participate in Upcoming Investor Conferences
2026-08-18 · Why Eli Lilly (LLY) Stock Is Up Today
2026-08-18 · Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals
2026-08-17 · OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook
2026-08-17 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-08-17 · Sector Update: Healthcare
Price (daily)
Full chart · RSI · MACD · patterns